Welcome to issue 36 of Multiple Myeloma Research Review. The use of ixazomib-based induction therapy in routine clinical practice is relatively uncommon for several reasons, so the first study for this issue is useful, as it describes the effectiveness and safety of such treatment in a multicentre cohort of real-world patients. US research has confirmed...Continue Reading

This article was originally published on Multiple Myeloma Today ABSTRACT BACKGROUND: Patients with hematological malignancies (HM), including multiple myeloma (MM), frequently suffer from immune deficiency-associated infectious complications because of both the disease and the treatment. Alarming results from China and the UK confirm the vulnerability of HM patients to severe acute respiratory syndrome coronavirus 2...Continue Reading